Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander?
- PMID: 37210596
- DOI: 10.1093/eurjpc/zwad140
Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander?
Abstract
Aims: Heart failure with preserved ejection fraction (HFpEF) is a condition that commonly coexists with type 2 diabetes mellitus (T2DM) and obesity. Whether the obesity-related survival benefit generally observed in HFpEF extends to individuals with concomitant T2DM is unclear. This study sought to examine the prognostic role of overweight and obesity in a large cohort of HFpEF with and without T2DM.
Methods and results: This large-scale cohort study included patients with HFpEF enrolled between 2010 and 2020. The relationship between body mass index (BMI), T2DM, and survival was assessed. A total of 6744 individuals with HFpEF were included, of which 1702 (25%) had T2DM. Patients with T2DM had higher BMI values (29.4 kg/m2 vs. 27.1 kg/m2, P < 0.001), higher N-terminal pro-brain natriuretic peptide values (864 mg/dL vs. 724 mg/dL, P < 0.001), and a higher prevalence of numerous risk factors/comorbidities than those without T2DM. During a median follow-up time of 47 months (Q1-Q3: 20-80), 2014 (30%) patients died. Patients with T2DM had a higher incidence of fatal events compared with those without T2DM, with a mortality rate of 39.2% and 26.7%, respectively (P < 0.001). In the overall cohort, using the BMI category 22.5-24.9 kg/m2 as the reference group, the unadjusted hazard ratio (HR) for all-cause death was increased in patients with BMI <22.5 kg/m2 [HR: 1.27 (confidence interval 1.09-1.48), P = 0.003] and decreased in BMI categories ≥25 kg/m2. After multivariate adjustment, BMI remained significantly inversely associated with survival in non-T2DM, whereas survival was unaltered at a wide range of BMI in patients with T2DM.
Conclusion: Among the various phenotypes of HFpEF, the T2DM phenotype is specifically associated with a greater disease burden. Higher BMI is linked to improved survival in HFpEF overall, while this effect neutralises in patients with concomitant T2DM. Advising BMI-based weight targets and weight loss may be pursued with different intensity in the management of HFpEF, particularly in the presence of T2DM.
Keywords: Diabetes; HFpEF; Obesity; Paradox.
Plain language summary
Individuals with HFpEF and concomitant diabetes show a distinct phenotype particularly associated with a higher disease burden and worse outcome. The obesity paradox observed in individuals with heart failure may not be generalized to HFpEF patients with concomitant diabetes.
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: None declared.
Comment in
-
No such thing as an innocent bystander: the conundrum of obesity, diabetes, and heart failure with preserved ejection fraction.Eur J Prev Cardiol. 2023 Sep 6;30(12):1245-1246. doi: 10.1093/eurjpc/zwad226. Eur J Prev Cardiol. 2023. PMID: 37421379 No abstract available.
Similar articles
-
Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study.PLoS Med. 2019 Sep 24;16(9):e1002916. doi: 10.1371/journal.pmed.1002916. eCollection 2019 Sep. PLoS Med. 2019. PMID: 31550265 Free PMC article.
-
Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case-control study in individuals aged 65-80 years.Cardiovasc Diabetol. 2023 Apr 28;22(1):97. doi: 10.1186/s12933-023-01835-2. Cardiovasc Diabetol. 2023. PMID: 37118820 Free PMC article.
-
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction.Eur J Prev Cardiol. 2021 Aug 9;28(9):948-955. doi: 10.1177/2047487320927610. Epub 2020 Jun 2. Eur J Prev Cardiol. 2021. PMID: 34402870
-
Obesity and heart failure with preserved ejection fraction: a paradox or something else?Heart Fail Rev. 2019 May;24(3):379-385. doi: 10.1007/s10741-018-09766-x. Heart Fail Rev. 2019. PMID: 30610456 Review.
-
Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis.Clin Res Cardiol. 2019 Feb;108(2):119-132. doi: 10.1007/s00392-018-1302-7. Epub 2018 Jun 27. Clin Res Cardiol. 2019. PMID: 29951802 Review.
Cited by
-
The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis.Heart Fail Rev. 2025 Sep;30(5):991-1004. doi: 10.1007/s10741-025-10523-0. Epub 2025 May 21. Heart Fail Rev. 2025. PMID: 40399552 Review.
-
Obesity and Heart Failure: Mechanistic Insights and the Regulatory Role of MicroRNAs.Genes (Basel). 2025 May 28;16(6):647. doi: 10.3390/genes16060647. Genes (Basel). 2025. PMID: 40565538 Free PMC article. Review.
-
Sex differences in the association between nutritional status and in-hospital mortality in HFpEF patients.ESC Heart Fail. 2025 Aug;12(4):2499-2506. doi: 10.1002/ehf2.15332. Epub 2025 May 21. ESC Heart Fail. 2025. PMID: 40396460 Free PMC article.
-
Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis.Clin Res Cardiol. 2025 Jun 10. doi: 10.1007/s00392-025-02694-5. Online ahead of print. Clin Res Cardiol. 2025. PMID: 40493069
-
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01166-7. Online ahead of print. Nat Rev Cardiol. 2025. PMID: 40544173 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical